(secondQuint)A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL.

 A multi-center treatment study assessing the efficacy and safety of an immunotherapeutic vaccine (DPX-Survivac) combined with low dose cyclophosphamide.

 Subjects with measurable, histologically proven DLBCL expressing survivin will be treated in this open-label, single arm study.

 Survivin is a protein commonly over-expressed in many types of cancer, including DLBCL.

.

 A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL@highlight

This phase 2 study is designed to assess the efficacy and safety of DPX-Survivac plus low dose cyclophosphamide in subjects with recurrent diffuse large B-cell lymphoma (DLBCL) who are not eligible for transplant.

